SCHEMBL21726329

SCHEMBL21726329

COc1cc(OC)c(F)c(-c2ccc3cnn(PI)c3c2)c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 1/20 0.34
MAP4K1 Q92918 1/20 0.34
CYP11B1 P15538 3/20 0.33
CYP11B2 P19099 3/20 0.33
CYP17A1 P05093 1/20 0.33
CYP1A1 P04798 1/20 0.32
CYP1B1 Q16678 1/20 0.32
FGFR3 P22607 2/20 0.32
FGFR1 P11362 2/20 0.32
FGFR2 P21802 2/20 0.32
FGFR4 P22455 1/20 0.32
KDR P35968 1/20 0.32
METAP2 P50579 1/20 0.32
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
HTR2B P41595 1/20 0.32
BRD4 O60885 3/20 0.32
CYP3A4 P08684 2/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21726330 0.83 MAP4K1 (0.34) MAP4K1CYP11B1CYP11B2FGFR2FGFR4
SCHEMBL21726306 0.80 ABL1 (0.44) CYP11B1CYP11B2CYP1A1CYP1B1FGFR3
SCHEMBL21726308 0.79 METAP2 (0.35) FGFR3FGFR1FGFR2FGFR4KDR
SCHEMBL21726299 0.74 FGFR4 (0.46) CYP11B1CYP11B2FGFR3FGFR1FGFR2
SCHEMBL17530960 0.72 RXRA (0.43) LRRK2MAP4K1FGFR3FGFR1FGFR2
SCHEMBL17531002 0.70 FGFR1 (0.57) FGFR3FGFR1FGFR2METAP2ALDH1A1
SCHEMBL15618641 0.70 ABL1 (0.40) CYP11B1CYP11B2CYP17A1FGFR4ESR1
SCHEMBL21726304 0.64 RAB9A (0.43) CYP1A1CYP1B1CYP3A4CYP2C9CYP2C19
SCHEMBL17531001 0.64 HDAC6 (0.42) FGFR3FGFR1FGFR2FGFR4KDR
SCHEMBL22753215 0.63 HTR2A (0.49) CYP11B1CYP11B2HTR2AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10562900-B2 Indazole compounds as FGFR kinase inhibitor, preparation and use thereof SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) 2020-02-18 US disclosed
US-20170275291-A1 INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITOR, PREPARATION AND USE THEREOF SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) 2017-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562900-B2 Indazole compounds as FGFR kinase inhibitor, preparation and use thereof FGFR1, FGFR2, FGFR3 LRRK2 241/4885MAP4K1 323/4885CYP11B1 286/4885
US-20170275291-A1 INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITOR, PREPARATION AND USE THEREOF FGFR1, FGFR2, FGFR3 LRRK2 241/4885MAP4K1 323/4885CYP11B1 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.